Skip to main content

Table 2 Optimal drug treatment in short-term signalling

From: Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines

Cell line

AKT

ERK1/2

p70S6K

BT474

-

PE

PE

HCC1954

PT E

E

P E

SKBR3

PTE

E

PTE

  1. The table summarises the optimal drug treatments for the short-term data, leading to inactive AKT, ERK1/2 and p70S6K, respectively. In case of a significant (p-value < 0.05) combined influence of both, drug treatment and time, on the protein signal intensity, a Wilcoxon rank sum test was conducted for the measurements at time point 60 minutes, testing for significantly (p-value < 0.05) smaller intensity values under the drug treatment compared to the control measurement. The drug treatment with the smallest p-value was considered as the optimal inhibitor. No inferred significant positive drug effect is denoted by ‘-’. The therapeutics erlotinib, trastuzumab and pertuzumab are abbreviated by their first letters. More than one letter denotes drug combinations. The growth factors EGF and HRG were added in combination to the cell lines and permanently active in the simulated perturbation conditions. The column Cell line holds the cell lines under consideration. The columns AKT, ERK1/2 and p70S6K hold the optimal drug combinations for each target. If those were confirmed by the attractor states (0) of perturbation simulations, they are printed in bold.